CSL, MedImmune Inc. deal

CSL's ZLB Behring LLC subsidiary completed its acquisition of MEDI's CytoGam cytomegalovirus (CMV) immune globulin to prevent CMV disease associated with transplantation (see BioCentury, Nov. 13, 2006). MEDI will receive $50 million up front and is eligible for up to $70 million in sales milestones. MEDI does not break out sales of CytoGam. ...